Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Takeda gets license to Hutchmed cancer compound
by Gina Vitale
January 29, 2023
| A version of this story appeared in
Volume 101, Issue 4
Takeda Pharmaceutical has entered an agreement with HutchMed to license the Chinese pharmaceutical firm’s tyrosine kinase inhibitor fruquintinib. Takeda will pay $400 million up front and up to $730 million in further potential payments. Fruquintinib is intended to treat refractory metastatic colorectal cancer, and the companies say the deal bolsters Takeda’s oncology portfolio. Takeda will get an exclusive worldwide license other than in China, Hong Kong, and Macau for the development and commercialization of the drug.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X